Gang Liu

US Patent:

7948042, May 24, 2011

Filed:

Mar 3, 2009

Appl. No.:

12/397183

Inventors:

Chun Ning Lau - Diamond Bar CA, US
Gang Liu - Riverside CA, US
Jairo Velasco, Jr. - Riverside CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

H01L 29/84

US Classification:

257415, 257417, 257419, 257E43002, 257E43003, 257E43007, 257E27005, 257E27046, 257E27064

Abstract:

A multi-level lithography processes for the fabrication of suspended structures are presented. The process is based on the differential exposure and developing conditions of several a plurality of resist layers, without harsher processes, such as etching of sacrificial layers or the use of hardmasks. These manufacturing processes are readily suited for use with systems that are chemically and/or mechanically sensitive, such as graphene. Graphene p-n-p junctions with suspended top gates formed through these processes exhibit high mobility and control of local doping density and type. This fabrication technique may be further extended to fabricate other types of suspended structures, such as local current carrying wires for inducing local magnetic fields, a point contact for local injection of current, and moving parts in microelectromechanical devices.

US Patent:

20140057914, Feb 27, 2014

Filed:

Aug 23, 2013

Appl. No.:

13/974261

Inventors:

Maria Emilia DiFrancesco - Houston TX, US
Alessia Petrocchi - Houston TX, US
Joe Marszalek - Houston TX, US
Gang Liu - Houston TX, US

Assignee:

Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center - Houston TX

International Classification:

C07D 413/04
A61K 31/496
A61K 45/06
C07D 413/14
A61K 31/5377
A61K 31/454
A61K 31/4245
C07D 417/04

US Classification:

5142362, 514364, 548131, 51425402, 544369, 51425403, 544364, 5142531, 544138, 546209, 514326

Abstract:

The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.

US Patent:

20140073634, Mar 13, 2014

Filed:

Aug 23, 2013

Appl. No.:

13/974266

Inventors:

Maria Emilia DiFrancesco - Houston TX, US
Alessia Petrocchi - Houston TX, US
Joe Marszalek - Houston TX, US
Gang Liu - Houston TX, US
Zhijun Kang - Houston TX, US
Chris Carroll - Houston TX, US
Timothy McAfoos - Houston TX, US
Barbara Czako - Houston TX, US

Assignee:

Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center - Houston TX

International Classification:

C07D 417/14
A61K 31/501
C07D 413/14
C07D 401/06
C07D 237/24
A61K 31/541
C07D 413/04
C07D 213/82
A61K 31/5377
A61K 31/4545
A61K 31/444
A61K 31/4439
A61K 45/06
A61K 31/496

US Classification:

5142278, 51425202, 544238, 544364, 5142531, 51425312, 544114, 5142365, 546194, 514318, 546256, 514333, 544131, 5142362, 51425219, 544333, 5462694, 514340, 51425205, 544 582

Abstract:

The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.

US Patent:

20220267311, Aug 25, 2022

Filed:

Mar 10, 2022

Appl. No.:

17/654301

Inventors:

- Austin TX, US
Gang LIU - Sugar Land TX, US
Kang LE - Sugar Land TX, US
Jason CROSS - Pearland TX, US
Philip JONES - Houston TX, US

International Classification:

C07D 413/14
C07D 401/04
C07D 471/04
C07D 417/14
C07D 401/14
C07D 405/14

Abstract:

Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).

US Patent:

20210206745, Jul 8, 2021

Filed:

Dec 16, 2020

Appl. No.:

17/124051

Inventors:

- Austin TX, US
Michael J. SOTH - Sugar Land TX, US
Jason P. BURKE - Houston TX, US
Kang LE - Sugar Land TX, US
Gang LIU - Sugar Land TX, US

International Classification:

C07D 401/14
A61K 31/501
A61K 45/06
A61P 35/00
A61K 31/337

Abstract:

Disclosed herein is the compound (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide, and salt forms and polymorphs thereof demonstrating improved exposure after oral dosing. Methods of inhibition GLS1 activity in a human or animal subject are also provided.

US Patent:

20200407353, Dec 31, 2020

Filed:

Jul 10, 2020

Appl. No.:

16/925974

Inventors:

- Austin TX, US
Philip JONES - Houston TX, US
Timothy HEFFERNAN - Sugar Land TX, US
Matthew M. HAMILTON - Missouri City TX, US
Zhijun KANG - Richmond TX, US
Michael J. SOTH - Sugar Land TX, US
Jason P. BURKE - Houston TX, US
Kang LE - Sugar Land TX, US
Christopher Lawrence CARROLL - Houston TX, US
Wylie S. PALMER - Houston TX, US
Richard LEWIS - Missouri City TX, US
Timothy MCAFOOS - Pearland TX, US
Barbara CZAKO - Bellaire TX, US
Gang LIU - Sugar Land TX, US
Jay THEROFF - Manvel TX, US
Zachary HERRERA - El Cerrito CA, US
Anne YAU - Houston TX, US

International Classification:

C07D 417/14
A61K 31/4439
A61K 45/06
C07D 417/06
A61K 31/433
C07D 403/06
A61K 31/501
C07D 401/14
A61K 31/454
A61K 31/4192
C07D 405/14
C07D 403/14
A61K 31/444
C07D 493/08
A61K 31/497

Abstract:

Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I:Methods of inhibition GLS1 activity in a human or animal subject are also provided.

US Patent:

20190308978, Oct 10, 2019

Filed:

Apr 8, 2019

Appl. No.:

16/378309

Inventors:

- Austin TX, US
Michael J. SOTH - Sugar Land TX, US
Gang LIU - Sugar Land TX, US
Philip JONES - Houston TX, US
Jason Bryant CROSS - Pearland TX, US
Timothy Joseph MCAFOOS - Pearland TX, US
Christopher L. CARROLL - Houston TX, US
Richard T. LEWIS - Missouri City TX, US

International Classification:

C07D 487/04
C07D 519/00

Abstract:

The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.

US Patent:

20190270736, Sep 5, 2019

Filed:

May 14, 2019

Appl. No.:

16/412050

Inventors:

- Austin TX, US
Philip JONES - Houston TX, US
Timothy HEFFERNAN - Sugar Land TX, US
Matthew M. HAMILTON - Missouri City TX, US
Zhijun KANG - Richmond TX, US
Michael J. SOTH - Sugar Land TX, US
Jason P. BURKE - Houston TX, US
Kang LE - Sugar Land TX, US
Christopher Lawrence CARROLL - Houston TX, US
Wylie S. PALMER - Houston TX, US
Richard LEWIS - Missouri City TX, US
Timothy MCAFOOS - Pearland TX, US
Barbara CZAKO - Bellaire TX, US
Gang LIU - Sugar Land TX, US
Jay THEROFF - Manvel TX, US
Zachary HERRERA - El Cerrito CA, US
Anne YAU - Houston TX, US

International Classification:

C07D 417/14
A61K 31/497
C07D 493/08
A61K 31/444
C07D 403/14
C07D 405/14
A61K 31/4192
A61K 31/4439
C07D 401/14
A61K 31/501
C07D 403/06
A61K 31/433
C07D 417/06
A61K 45/06
A61K 31/454

Abstract:

Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I:Methods of inhibition GLS1 activity in a human or animal subject are also provided.